Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cusatuzumab in Combination With Background Therapy for AML
NCT04150887Phase 1Active, not recruiting
- Sponsor
- OncoVerity
- Start
- Dec 2019
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of cusatuzumab in acute myeloid leukemia (AML) (2 cohorts), sponsored by OncoVerity. Primary endpoint: Adverse Events at 42 months. Started Dec 2019; status: active, not recruiting.
02
Drugs
cusatuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04150887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150887.